This review aims to provide an extensive overview of the literature on the clinical
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …

With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need
for more accurate drug dosing has become evident. Personalized immunosuppressive …

Efficacy and safety of mycophenolate mofetil (MMF) may be optimized with individualized
doses based on therapeutic monitoring of its active metabolite, mycophenolic acid (MPA). In …

A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide
immunosuppression with mycophenolate mofetil was held in New York in December 2004 …

Background. Fixed-dose mycophenolate mofetil (MMF) reduces the incidence of acute
rejection after solid organ transplantation. The Fixed-Dose Concentration Controlled trial …

In mycophenolate mofetil (MMF)-treated organ transplant recipients, lower mycophenolic
acid (MPA) plasma concentrations have been found in cyclosporine (CsA) compared with …

Large between-and within-patient variability has been observed in the pharmacokinetics of
mycophenolic acid (MPA). However, conflicting results exist about the influence of patient …

Background. Mycophenolic acid (MPA) is glucuronidated by uridine diphosphate-
glucuronosyltransferases (UGTs) to its pharmacologically inactive 7-O-glucuronide …

Background Mycophenolic acid (MPA), an effective immunosuppressive drug used in renal
transplantation, is extensively glucuronidated by several uridine diphosphate …

Detailed knowledge regarding the influence of hepatic transport proteins on drug disposition
has advanced at a rapid pace over the past decade. Efflux transport proteins located in the …